Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

Echocardiography may be at the vanguard for early and rapid detection of heart issues indicative of Duchenne muscular ...

The first few months of 2025 brought hope to the rare disease community. Food and Drug Administration leadership promised ...

The city of Rockford dedicated a memorial plaque to one of their own, who died in November to a form of muscular dystrophy.

The Duchenne muscular dystrophy market is witnessing steady growth driven by advancements in gene therapies, exon-skipping drugs, and corticosteroid alternatives. Increasing diagnosis rates ...

For adults with Duchenne muscular dystrophy, swallowing-related impairments are associated with age, inspiratory muscle strength, and autonomic dysfunction, say the results of a new study. CMR ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...

Global Duchenne Muscular Dystrophy Drugs Market Report 2023: Sector is Expected to Reach $4 Billion by 2028 at a CAGR of 11.88% - ResearchAndMarkets.com May 18, 2023 07:21 AM Eastern Daylight Time ...

Duchenne muscular dystrophy has a prevalence of 1 in 35,000 males. [12] The symptoms of Duchenne muscular dystrophy initially include delayed motor milestones and weakness of the proximal muscles ...